"Darunavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.
| Descriptor ID |
D000069454
|
| MeSH Number(s) |
D02.065.884.438 D02.241.081.251.222 D02.886.590.700.400 D03.383.312.303
|
| Concept/Terms |
TMC 114- TMC 114
- 114, TMC
- TMC114
- TMC-114
|
Below are MeSH descriptors whose meaning is more general than "Darunavir".
Below are MeSH descriptors whose meaning is more specific than "Darunavir".
This graph shows the total number of publications written about "Darunavir" by people in this website by year, and whether "Darunavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Darunavir" by people in Profiles.
-
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022 06; 25(6):e25905.
-
Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa. BMC Infect Dis. 2022 May 12; 22(1):456.
-
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019 09; 6(9):e588-e600.
-
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2019 07; 6(7):e428-e437.
-
Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility. Biochem J. 2019 01 31; 476(2):375-384.
-
Association of antiretroviral therapy with brain aging changes among HIV-infected adults. AIDS. 2018 09 10; 32(14):2005-2015.
-
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. PLoS One. 2015; 10(12):e0145772.
-
Outcomes in treatment with darunavir/ritonavir in ART-experienced paediatric patients. S Afr Med J. 2015 Apr 08; 105(5):330-1.
-
Darunavir: in treatment-experienced pediatric patients with HIV-1 infection. Paediatr Drugs. 2010 Apr 01; 12(2):123-31.